|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
| City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Anne Cassity |
Date | 1/20/2026 7:12:06 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Controlled Substances Prescribing & Dispensing;
Comments to DOJ & DEA on "Ensuring Lawful Governance and Implementing the Presidents 'Department of Government Efficiency' Deregulatory Initiative";
Comments to DEA on "Special Registrations for Telemedicine and Limited State Telemedicine Registrations [Docket No. DEA-407]"
Comments to DEA on "Update to DEA Registration Process for Pharmacists to Reflect State Law Changes"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Drug Enforcement Administration (DEA), Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.891, the Bipartisan Health Care Act;
S.882, the Patients Before Middlemen Act;
S.927, the Protecting Pharmacies in Medicaid Act;
H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act;
H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act;
Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169);
Long-Term Care Pharmacy at Home Services in Medicare;
Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)'
H.R.1, the One Big Beautiful Bill Act
Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program";
Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)"
Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form";
H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
H.R.4317, the PBM Reform Act;
H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act;
Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]";
Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]";
Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]";
Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]";
H.R.5256, the 340B ACCESS Act;
S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act;
S.3345, the PBM Price Transparency and Accountability Act;
H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act;
Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care;
CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 2214, the Delinking Revenue from Unfair Gouging Act;
H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025;
H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
H.R. 1, the One Big Beautiful Bill;
Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]";
LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms;
Comments to OMB on "Re: Request for Information: Deregulation";
Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs;
Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients";
Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting";
H.R.5316, the Drug Shortage Compounding and Patient Access Act;
H.R.5256, the 340B ACCESS Act;
Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy";
H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities;
S.3345, the PBM Price Transparency and Accountability Act;
H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act;
H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act];
H.R. 6703, the Lower Health Care Premiums for All Americans Act;
H.R.5133, the Patient's Right to Know Their Medication Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S.587/1301, The Death Tax Repeal Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
S.526, the Pharmacy Benefit Manager Transparency Act of 2025;
S.527, the Prescription Pricing for the People Act of 2025;
Comments to Department of Labor RE: "Re: Reforming Pharmacy Benefit Manager (PBM) Compensation Practices";
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
TRICARE Pharmacy Network Oversight & Changes;
National Defense Authorization Act for Fiscal Year 2026;
H.R. 6400,the RxACCESS Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025;
H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
H.R.1, the One Big Beautiful Bill Act;
H.R.5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TEC
16. Specific lobbying issues
Comments to HHS on "HIPAA Security Rule To Strengthen the Cybersecurity of Electronic Protected Health Information [HHS-OCR-0945-AA22]";
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anne |
Cassity |
|
|
|
Ronna |
Hauser |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Comments to CBP on "June 14, 2024, Internal Advice Letter H283420";
Comments to on "Re: Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [XRIN 0694- XC120]";
17. House(s) of Congress and Federal agencies Check if None
U.S. Customs & Border Protection, White House Office, Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Steve |
Postal |
|
|
|
Anne |
Cassity |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Comments to the White House on the Corporate Transparency Act implementations (NDAA; P.L.116-283);
17. House(s) of Congress and Federal agencies Check if None
White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Huser |
|
|
|
Steve |
Postal |
|
|
|
Anne |
Cassity |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |